Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population

Br J Haematol. 2020 Feb;188(3):e24-e27. doi: 10.1111/bjh.16282. Epub 2019 Nov 19.

¹ Service des Maladies du Sang, CHU Lille, Lille, France.
² Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Université Sorbonne, INSERM UMRs 938, Paris, France.
³ Service d'Hématologie, Hôpital Saint-Vincent, GHICL, Lille, France.
⁴ Service d'Hématologie, CH Arras, Arras, France.
⁵ Service de Médecine Interne, CH Abbeville, Abbeville, France.
⁶ Service d'Hématologie, CH Dunkerque, Dunkerque, France.
⁷ Institut de Pharmacie, CHU Lille, Lille, France.
⁸ Service d'Hématologie, CH Lens, Lens, France.
⁹ Service d'Anatomo-pathologie, Centre de Biologie Pathologie, CHU Lille, Lille, France.
¹⁰ Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

No abstract available

Keywords: AL-Amyloidosis; daratumumab; frailty.

Publication types